As earnings reports continue to roll in, investors may be taking a closer look at companies that they own. Staying on top of the most recent releases may help investors figure out if the company is well-positioned for future success. Taking a look at some earnings projections, we note that the current quarter EPS consensus estimate for Genomic Health, Inc. (NASDAQ:GHDX) is 0.09. This EPS estimate consists of 8 sell-side analysts taken into consideration by Zacks Research. For the last reporting period, the company reported a quarterly EPS of 0.03. Sell-side analysts often provide their best researched estimates for what the company will report. These estimates carry a lot of weight on Wall Street and the investing community. When a company reports actual earnings results, the surprise factor may cause the stock price to fluctuate more than normal. Investors will often pay added attention to a company that has surpassed expectations by a wide margin.
As the next round of earnings reports come into the spotlight next quarter, investors may be deciding how to get into the best position to make the most profitable trades. Earnings reports have the ability to influence stock prices dramatically. Sometimes it can be hard to figure out which way the price will go even if the reported numbers are up to snuff. Some investors enjoy the frantic trading opportunities around earnings reports, and others will stay as far away as possible. Even if the investor isn’t planning on making any moves during earnings season, it may be wise to follow what companies are reporting. If the numbers from a certain holding come in way out of whack, it may be necessary to do some in-depth research to try and find out the reason. Investors that make sure that all the bases are covered will typically find it easier to make sense out of certain anomalies that pop up in the markets from time to time. Putting in the extra time and effort to understand the ins and outs of a particular stock may help boost the novice investor up to the next level. Every investor wants their trades to be profitable, and doing that little extra piece of homework could be just what the finance doctor ordered for staying on top of the stock market.
Wall Street analysts often give buy/sell/hold ratings for the companies that they track. Investors have the ability to view these sell-side ratings in order to help with their own stock research. Analyst ratings may have different interpretations. According to analysts polled by Zacks Research, the current average broker rating on shares of Genomic Health, Inc. (NASDAQ:GHDX) is 2.91. This rating uses a scale between 1 and 5. Following this scale, a rating of 1 would represent a Strong Buy, and a rating of 5 would indicate a Strong Sell recommendation. Out of all these analysts offering ratings, 2 have rated the stock a Strong Buy or Buy, according to Zacks Research.
Shifting the focus to some possible support and resistance levels on shares of Genomic Health, Inc. (NASDAQ:GHDX), we note that the 52-week high is currently $36.94, and the 52-week low is currently $26.71. When shares are trading near to the 52-week high or 52-week low, investors may be watching for a break through either level. Investors may also be watching historical price action. Over the past 12 weeks, the stock has moved 15.1%. Going back to the start of the year, we can see that shares have moved 23.17%. Over the last 4 weeks, shares have seen a change of 23.76%. Over the last 5 trading days, the stock has moved 8.77%. Checking in on recent session activity, we have seen that the stock has been trading near the $36.2 mark.
Looking further at shares of Genomic Health, Inc. (NASDAQ:GHDX), we have noticed that the current consensus target price is $32.28. Wall Street analysts have the ability to create price target estimates for where they think the stock will be moving in the near-term. Because price target projections can differ from one analyst to the next, they may span a wide range of values. Many investors will closely track target prices, and they tend to pay extra close attention when analysts make revisions to those targets.